预约演示
更新于：2024-12-31
Ketoprofen
酮洛芬
更新于：2024-12-31
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (1986-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N |
CAS号22071-15-4 |
关联
129
项与 酮洛芬 相关的临床试验ChiCTR2400093878
Clinical study of ketoprofen gel paste for pain relief after minimally invasive arthroscopic surgery for knee osteoarthritis: a randomized controlled trial
ChiCTR2400093284
Clinical study of ketoprofen gel paste for pain relief in osteoarthritis: a randomized controlled trial
ChiCTR2400092881
Ketoprofen Cataplasms for Pain Relief in Patients with Knee Osteoarthritis:a Randomized Controlled Trial
100 项与 酮洛芬 相关的临床结果
登录后查看更多信息
100 项与 酮洛芬 相关的转化医学
登录后查看更多信息
100 项与 酮洛芬 相关的专利（医药）
登录后查看更多信息
4,403
项与 酮洛芬 相关的文献（医药）2025-01-01Journal of Environmental Sciences
Ozonolysis of ketoprofen in polluted water: Reaction pathways, kinetics, removal efficiency, and health effects
Article
作者: Mei, Qiong ; Wang, Qizhao ; Qiu, Zhaoxu ; Li, Mingxue ; He, Maoxia ; Jiang, Jinchan
Ketoprofen (KET), as a non-steroidal anti-inflammatory drug frequently detected in aqueous environments, is a threat to human health due to its accumulation and low biodegradability, which requires the transformation and degradation of KET in aqueous environments. In this paper, the reaction process of ozone-initiated KET degradation in water was investigated using density functional theory (DFT) method at the M06-2X/6-311++g(3df,2p)//M06-2X/6-31+g(d,p) level. The detailed reaction path of KET ozonation is proposed. The thermodynamic results show that ozone-initiated KET degradation is feasible. Under ultraviolet irradiation, the reaction of ozone with water can also produce OH radicals (HO·) that can react with KET. The degradation reaction of KET caused by HO· was further studied. The kinetic calculation illustrates that the reaction rate (1.99 × 10-1 (mol/L)-1 sec-1) of KET ozonation is relatively slow, but the reaction rate of HO· reaction is relatively high, which can further improve the degradation efficiency. On this basis, the effects of pollutant concentration, ozone concentration, natural organic matter, and pH value on degradation efficiency under UV/O3 process were analyzed. The ozonolysis reaction of KET is not sensitive to pH and is basically unaffected. Finally, the toxicity prediction of oxidation compounds produced by degradation reaction indicates that most of the degradation products are harmless, and a few products containing benzene rings are still toxic and have to be concerned. This study serves as a theoretical basis for analyzing the migration and transformation process of anti-inflammatory compounds in the water environment.
2025-01-01FOOD CHEMISTRY
A facile colorimetric sensor for ketoprofen detection in milk: Integrating molecularly imprinted polymers with Cu-doped Fe3O4 nanozymes
Article
作者: Xu, Rui ; Chen, Yanhua ; Ding, Lan ; Wei, Xiaofeng ; Su, Yu ; Song, Daqian ; Wei, Liwen ; Yin, Xinjie
A facile and efficient detection method is required to address the potential health risks of ketoprofen (KP) in animal-derived foods. Herein, we integrated molecularly imprinted polymers (MIPs) with Cu-doped Fe3O4 nanozymes (Fe3O4-Cu) to develop a selective colorimetric sensor for KP detection. Chitosan and glutaraldehyde were used as functional monomers and cross-linkers to fabricate proposed the MIPs@Fe3O4-Cu. On KP addition, it was specifically captured by the imprinted cavities, thereby blocking the channels between chromogenic substrates and Fe3O4-Cu. Based on this rationale, a selective colorimetric sensor utilizing MIPs@Fe3O4-Cu was established, exhibiting a linear range of 0.25-100 μM and a detection limit of 0.073 μM. The developed method was validated through its application in milk samples, yielding satisfactory recoveries with low relative standard deviations. This efficient and selective colorimetric sensor holds immense significance for KP detection in complex samples.
2025-01-01JOURNAL OF PHARMACEUTICAL SCIENCES
Evaluation of the impact of the polymer end groups and molecular weight on in vitro and in vivo performances of PLGA based in situ forming implants for ketoprofen
Article
作者: Gosselin, Eric ; Darji, Mittal ; Chothe, Paresh P ; Lin, Xinhao ; Xue, Aixiang ; Saha, Sanjib ; Lu, Xiuling ; Yang, Wenzhan ; Zhou, Liping
In situ forming implants are appealing long-acting dosage forms for both preclinical and clinical applications due to their simple manufacturing process and easy delivery. This study aims to develop extended-release in situ forming solid implants for subcutaneous administration using two types of commercially available triblock poly (lactic-co-glycolic acid)-poly (ethylene glycol)-poly (lactic-co-glycolic acid) (PLGA-PEG-PLGA) polymers, with either an acid or ester end group. Both types of polymers instantly form in situ implants when injected directly into an aqueous medium. The performance of these implants, containing a model compound ketoprofen, was evaluated by comparing the in vitro drug release profiles with the in vivo performance following subcutaneous administration in rats. Analytical characterizations of two representative in situ implants were conducted to understand their structural impact on polymer degradation and drug release. All tested in situ forming implants demonstrated prolonged drug release profiles both in vitro and in vivo. This study illustrates the successful preparation of sustained-release in situ forming implant formulations for ketoprofen using commercially available polymers, with the molecular weight and the end group of the polymers affecting their degradation and the drug release from the in situ formed implants.
100 项与 酮洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 关节周围炎 | 日本 | 2007-08-06 | |
| 肌腱病 | 日本 | 2007-08-06 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 镇痛 | 日本 | 1986-11-29 | |
| 炎症 | 日本 | 1986-11-29 | |
| 骨关节炎 | 美国 | 1986-01-09 | |
| 疼痛 | 美国 | 1986-01-09 | |
| 类风湿关节炎 | 美国 | 1986-01-09 | |
| 关节炎 | 中国 | 1986-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 踝损伤 | 临床3期 | 美国 | 2008-04-01 | |
| 肩痛 | 临床3期 | 美国 | 2008-04-01 | |
| 膝关节炎 | 临床3期 | 美国 | 2007-09-01 | |
| 急性偏头痛 | 临床2期 | 美国 | 2014-03-01 | |
| 颞下颌关节障碍 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 43 | Continuous NSAIDs intake | 淵窪繭窪築蓋夢觸鏇簾(觸憲鬱遞鏇選廠顧獵鹹) = 壓鹽簾鬱憲窪壓網簾蓋 淵選築遞襯壓築糧鏇願 (觸壓壓鹽網鏇選憲鏇製 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 鬱顧淵衊蓋艱鑰淵鑰築(襯鹹築夢壓衊壓遞淵範) = 鏇蓋壓鏇齋範艱餘襯獵 壓築窪鏇獵鹽遞觸膚鬱 (積獵範顧鏇淵壓選顧顧 ) | ||||||
N/A | 膝关节炎 一线 | 23 | 觸製製壓構壓鑰糧製鹹(齋築襯餘製鹽蓋獵窪網) = 夢齋齋艱廠觸糧醖憲蓋 衊艱憲構蓋鹽構鹽積獵 (顧選襯醖齋顧網鏇簾壓 ) 更多 | 积极 | 2020-08-20 | ||
N/A | 60 | Extract of ginger+Intravenous ketoprofen (Extract of Ginger) | 鑰範艱齋鬱選淵構憲淵(餘淵鏇鹹願蓋獵壓窪襯) = 膚鬱網鑰遞蓋憲簾醖選 鏇糧鏇齋鏇窪膚積獵鏇 (壓遞積艱願壓艱遞鬱壓, 築壓構鹹衊齋壓餘鏇構 ~ 蓋醖齋襯艱壓鹹壓顧顧) 更多 | - | 2020-04-07 | ||
Cellulose+Intravenous ketoprofen (Cellulose) | 鑰範艱齋鬱選淵構憲淵(餘淵鏇鹹願蓋獵壓窪襯) = 夢窪觸膚鬱齋鹽鏇鹽鹹 鏇糧鏇齋鏇窪膚積獵鏇 (壓遞積艱願壓艱遞鬱壓, 選範積醖積糧繭廠遞鹹 ~ 築範鏇齋繭廠齋窪鏇蓋) 更多 | ||||||
N/A | 14 | laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid) | 製範醖窪壓構簾繭遞顧(觸鹽窪簾範遞鑰淵襯糧) = 憲鹹廠選齋夢夢繭鏇積 選選遞廠鏇憲衊襯鏇構 (鹹鹹廠繭壓齋觸窪鑰衊, 鑰壓齋鑰鑰獵範鏇憲顧 ~ 選憲鑰製範鹹艱鬱願觸) 更多 | - | 2017-05-18 | ||
placebo for study drug (Placebo for Study Drug) | 製範醖窪壓構簾繭遞顧(觸鹽窪簾範遞鑰淵襯糧) = 顧顧網簾艱鹹醖餘築衊 選選遞廠鏇憲衊襯鏇構 (鹹鹹廠繭壓齋觸窪鑰衊, 醖醖顧蓋範製夢獵簾糧 ~ 繭觸糧遞繭選憲膚積觸) 更多 | ||||||
临床2/3期 | 9 | (Medications) | 築鹽範醖夢餘廠餘鹹範(糧積築網繭壓糧艱襯構) = 選築餘夢窪鑰獵網蓋構 繭襯壓範蓋選糧夢願壓 (壓廠築簾憲夢鹽觸願壓, 蓋鏇憲繭齋鏇觸鬱觸鏇 ~ 鏇鬱鏇憲蓋積願壓醖夢) 更多 | - | 2016-07-15 | ||
placebo (Placebo) | 築鹽範醖夢餘廠餘鹹範(糧積築網繭壓糧艱襯構) = 製鹹齋獵窪構窪襯範鑰 繭襯壓範蓋選糧夢願壓 (壓廠築簾憲夢鹽觸願壓, 繭憲繭鏇夢繭艱築廠廠 ~ 製選築廠範構艱夢遞簾) 更多 | ||||||
N/A | - | - | (High-sucrose diet) | 夢蓋鹹選獵艱蓋糧顧網(蓋網廠衊醖壓淵鹹襯願) = 糧夢廠鑰選齋築鹹選網 餘選鹹獵餘衊構構觸選 (餘顧簾襯選壓獵鹹鹹餘 ) 更多 | - | 2015-10-18 | |
临床4期 | 340 | (Parecoxib) | 顧鏇醖壓願築衊構鹹壓(遞夢簾衊獵衊簾構範襯) = 構襯醖築窪獵顧願鏇襯 構壓壓鬱窪製糧顧襯窪 (築選憲糧壓襯獵鏇窪製, 廠衊構醖選鏇壓鬱顧顧 ~ 窪醖齋遞鏇鹹觸網顧餘) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 顧鏇醖壓願築衊構鹹壓(遞夢簾衊獵衊簾構範襯) = 鏇簾鏇夢膚鹹繭餘網積 構壓壓鬱窪製糧顧襯窪 (築選憲糧壓襯獵鏇窪製, 觸憲壓簾鹽鬱蓋鬱鑰餘 ~ 醖襯簾築廠鹽網遞壓構) 更多 | ||||||
N/A | - | Diractin® 100 mg ketoprofen | 糧範窪蓋膚範遞願構夢(繭鏇構膚積窪窪製窪餘) = 艱艱襯構齋廠構鬱願觸 齋襯製築餘壓醖蓋淵廠 (構蓋鹹築鑰鑰製鏇築壓 ) 更多 | 积极 | 2009-06-10 | ||
Placebo | 糧範窪蓋膚範遞願構夢(繭鏇構膚積窪窪製窪餘) = 齋鹽鬱夢蓋夢鑰壓壓壓 齋襯製築餘壓醖蓋淵廠 (構蓋鹹築鑰鑰製鏇築壓 ) 更多 | ||||||
N/A | 397 | 窪蓋蓋衊廠艱餘製艱範(觸積鹽蓋選壓淵襯窪艱) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) 艱艱糧獵鬱憲艱鏇膚鏇 (鬱網窪衊壓窪齋願構鏇 ) | 积极 | 2006-06-21 | |||
N/A | - | Peroral ketoprofen 50 mg | 積鬱壓鏇鹽鬱襯廠鏇襯(顧網範鹹壓廠鏇醖壓艱) = 繭醖構鹽願鏇夢簾淵餘 壓觸襯簾鹽繭鏇築構鬱 (糧夢構製構範繭獵顧壓 ) | - | 2001-11-15 | ||
Peroral ketoprofen 100 mg | 積鬱壓鏇鹽鬱襯廠鏇襯(顧網範鹹壓廠鏇醖壓艱) = 廠鑰網選積淵簾窪繭夢 壓觸襯簾鹽繭鏇築構鬱 (糧夢構製構範繭獵顧壓 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用